Summary: The legal action initiated on June 27, 2023, encompasses a diverse group of plaintiffs, including both minors and adults, who identify as transgender and reside in Florida. The defendants in this case are Joseph A. Ladapo, the Surgeon General of the Florida Department of Health, along with various members of the Florida Board of Medicine, the Florida Board of Osteopathic Medicine, and several State Attorneys. The plaintiffs are contesting Senate Bill 254 (SB 254) and the Transgender Medical Restrictions, which were introduced by the Surgeon General and endorsed by the members of the Florida Board of Medicine and the Florida Board of Osteopathic Medicine. These restrictions, which could potentially lead to disciplinary action against non-compliant doctors, are under scrutiny. The plaintiffs assert that SB 254's ban on established medical care for transgender minors infringes upon the fundamental rights of parents to make medical decisions for their children. They further argue that these restrictions contravene the federal Equal Protection Clause, as they discriminate based on transgender status and sex, without serving any legitimate governmental interest. The lawsuit also focuses on the standards of care for treating gender dysphoria in minors and adults, as outlined by ATH and the Endocrine Society. The plaintiffs argue that there is no valid medical reason to prevent Nurse Practitioners from prescribing or administering hormone therapy to transgender patients. The plaintiffs are seeking legal remedy for the alleged violation of their rights protected by the United States Constitution, specifically asserting that the Transgender Medical Restrictions contravene federal law. The lawsuit, filed under 42 U.S.C. § 1983, aims to prevent the defendants from enforcing these restrictions. The plaintiffs are seeking declaratory and injunctive relief, claiming that without such relief, they will suffer severe, ongoing, and irreparable harm. The lawsuit also disputes the Boards' prohibitions on care for transgender minors, established through rulemaking processes in 2022 and 2023. These prohibitions include sex reassignment surgeries, puberty blocking, hormone, and hormone antagonist therapies for minors, with an exception for those already receiving such treatments before the bans' effective date. The plaintiffs argue that these prohibitions disregard the established medical and scientific consensus that these treatments are medically necessary, safe, and effective for treating gender dysphoria. They further argue that these prohibitions contradict Florida's public policy, which grants parents the right to make medical decisions for their adolescent children.